TriSalus Life Sciences Reports Modest Revenue Growth Amid Rising Operating Losses
Event summary
- TriSalus Life Sciences reported Q2 2026 revenue of $11.4 million, up 1.7% year-over-year.
- Operating losses widened to $9.8 million from $7.3 million in the same period last year.
- Gross margins improved to 86.8% from 83.9%, driven by reduced cost per TriNav unit.
- Company maintained full-year revenue guidance of $54–$57 million, representing 19–26% growth over 2025.
- Cash and cash equivalents totaled $46.3 million as of June 30, 2026.
The big picture
TriSalus Life Sciences is navigating a period of modest revenue growth amid rising operating losses, typical for a medical technology company scaling its commercial footprint. The company's focus on improving gross margins and securing favorable reimbursement terms reflects broader industry trends toward value-based healthcare delivery. With $46.3 million in cash reserves and maintained full-year guidance, TriSalus aims to balance aggressive sales expansion with operational discipline.
What we're watching
- Revenue Growth Trajectory
- Whether TriSalus can sustain sequential revenue growth in the second half of 2026 as sales efforts ramp up.
- Operational Efficiency
- The pace at which cost reductions and gross margin improvements offset rising sales and marketing expenses.
- Regulatory Tailwinds
- How the CMS reimbursement rate for vascular embolization procedures will impact adoption of TriSalus' technology.
Related topics